DOCSLIB.ORG

Accelerating GPCR Drug Discovery and Development Products and Services for Target ID, Functional Screening, Lead Optimization, and QC Lot-Release Testing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Accelerating GPCR Drug Discovery and Development Products and Services for Target ID, Functional Screening, Lead Optimization, and QC Lot-Release Testing Accelerating GPCR Drug Discovery and Development Products and Services for Target ID, Functional Screening, Lead Optimization, and QC Lot-Release Testing What’sWhat’s Inside: Inside: x >650 GPCR Assays x x Functional Readouts x cAMP Calcium β-Arrestin Internalization Pharmacotrafficking Complete Solutions Ready-to-Use Kits Cell Lines Screening Services Toolbox GPCR Pathways and Assays G-protein coupled receptors (GPCRs) play a crucial role in many physiological functions and in the pathology of multiple diseases including cancer, endocrine, and metabolic disorders. These receptors represent the largest class of validated therapeutic targets. Over 30% of currently marketed drugs target these receptors, and many GPCRs are still active targets for drug discovery. Largest portfolio of validated products and services to accelerate your GPCR drug discovery. >400 functional assays measuring β-arrestin recruitment to over 90% of class A and B GPCRs, including assays for over 75 orphan GPCR targets >150 naturally-coupled Gi/o, Gs and Gq GPCR cell lines for measurement of cAMP and calcium >100 functional cell lines for receptor internalization and trafficking The assays are available as stable, clonal cell lines or complete ready-to-use kits optimized for small molecules or biologics. With over 700 peer-reviewed customer publications, these assays are the most trusted pharmacologically- relevant functional GPCR assays in the industry. cAMP Assays Measure intracellular cAMP with easy-to-use protocols Characterize ligand pharmacology with precision Reproducible performance with large assay windows and broad sensitivity ranges Gαs cAMP Gαi Calcium Assays Measure intracellular calcium flux in adherent or suspension cells Fast, highly sensitive, and low-cost, HTS-friendly platform Homogeneous protocol with large assay windows and broad sensitivity ranges Ca2+ β-Arrestin Assays Universal G-protein independent method to quantify GPCR activation Easy, add-and-read protocol optimized for screening to QC lot-release testing Multiplex with calcium or cAMP readouts for cost-effective screening β-arrestin and ligand bias analysis Internalization Assays Quantitative measurement of GPCR internalization, desensitization, and resensitization Simple chemiluminescent readout, without imaging Easy protocol enabling rapid lead optimization and ligand bias studies Pharmacotrafficking Assays Detect trafficking in functionally-restored mutant GPCRs Identify pharmacochaperones that correct protein misfolding-related diseases Quantitative chemiluminescent results without imaging Learn more about all GPCR platforms at discoverx.com/gpcr One GPCR Target, Multiple Functional Readouts Identify Functionally Selective Ligands Biased GPCR ligands represent exciting opportunities for developing better and safer drugs, by selectively promoting the desired biological effect relevant for the disease, while simultaneously deselecting the deleterious ones1,2. DiscoverX provides the largest portfolio of GPCR assays and a unique service, “gpcrBIAS” for characterization of ligand bias. These assays offer wide assay windows to allow different functional readouts in single or multiplexed mode for the same GPCR target in a single cell line, to generate a unique efficacy profile of the ligand and capture the full repertoire of possible signaling responses. 20000 cAMP Acetylcholine Carbachol 15000 cAMP Oxotremorine-M 10000 RLU 5000 0 10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 nist sin β-Arrestin 125000 100000 75000 RLU 50000 β-arrestin CHRM2 25000 0 10 -10 10 -8 10 -6 10 -4 10 -2 [M] Internalization 10000 7500 RLU 5000 2500 0 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 10 -3 10 -2 [M] The cholinergic receptor, muscarinic 2 (CHRM2), was expressed in CHO-K1 cells and three assay formats were created for cAMP, β-arrestin, and internalization readouts. Dose-response curves were generated for multiple ligands to determine their functional selectivity. Acteylcholine and Carbachol showed similar agonist responses and potencies in all three readouts. Oxotremorine-M showed similar cAMP response, but as a partial agonist in recruiting β-arrestin and a strong agonist for receptor internalization. Interrogating the three pathways for the same target revealed differences in the mechanism of action of each ligand. These assays provide the ability to quantify “bias” for each potential drug candidate to help determine the overall quality of efficacy possessed by each drug. “… examples of β-arrestin and G protein biased ligands demonstrate how our new understanding of these two types of signaling pathways, gained initially at a biochemical level, can potentially be harnessed for therapeutic benefit.”— Robert Lefkowitz, Ph.D. 2012 Nobel Prize in Chemistry. Calcium and β-Arrestin Detection in the Same Well Several GPCR agonists activate multiple signaling pathways differentially. An increasing awareness of the subtleties of GPCR receptor signaling and the potential for ligand bias requires multiple endpoints to be monitored in any screening campaign. DiscoverX offers Gq-coupled arrestin targets as clonal cell lines or Ready-to-Use kits, to monitor intracellular calcium flux in real time, followed by the recruitment ofβ -arrestin in the same cell line or in a single well. This HTS-compatible duplexed assay increases your screening capabilities, removes challenges of running multiple assays, reduces data complexity, and provides significant cost savings and time efficiencies. Calcium β-Arrestin 200 100000 BDKRB1 EC50 = 12.2 native CHO-K1 75000 S:B = 12.7 X 100 50000 RFU RLU ∆ 25000 0 0 -12 -11 -10 -9 -8 -7 -6 -5 10 -12 10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 10 10 10 10 10 10 10 Bradykinin [M] Bradykinin [M] ® Naturally Gq-coupled PathHunter β-arrestin cell line expressing the Bradykinin B1 Receptor (BDKRB1) was first monitored for calcium mobilization using the Calcium No WashPLUS Kit as a fluorescent readout.β -arrestin recruitment was then analyzed in the same well using the PathHunter Detection Reagents. These duplexed assay provide a simple and efficient approach for measuring different signaling pathways for the same GPCR and define potency ranking of GPCR modulators. References: 1. Violin JD and Lefkowitz RJ. β-Arrestin-biased ligands at seven-transmembrane receptors. Trends in Pharmacological Sciences. 2007, 28 (8), 416–422. 2. Kingwell K. Pioneering biased ligand offers efficacy with reduced on-target toxicity. Nature Reviews Drug Discovery 2015, 14 (12), 809–810 Choose the Solution that Best Meets Your Program Needs Whether you are developing small molecules or biologics, DiscoverX provides you with a choice of different product formats to meet your specific research needs. Learn more at discoverx.com/gpcr. Human | Orphans | Orthologs >300 GPCR Targets | >650 Cell Lines Multiplexed Readouts Pharmacological Activity . cAMP . β-Arrestin . Agonism . Ligand Bias . Calcium . Internalization . Antagonism . Allosteric Modulation Test Assay Quickly Screen In-House Lead Optimization Build Your Own Assay Ready-to-Use Kits Cell Lines Screening Services Toolbox . Bioassay and eXpress . Stable cell lines for . Leading provider of . Rapidly develop assays kitsinclude cryopreserved continuous cell culture GPCR screening and for any GPCR with a ready-to-use cells and all and in-house banking profiling services β-arrestin, trafficking, or required reagents internalization readout . Save time and money, . Deliver consistent assay . Screen and profile . Create your own cell- no cell culture needed performance guaranteed against the broadest based assays in any for at least 10 passages menu of cell-based dividing mammalian functional assays with cell type the fastest turnaround time . Ease of assay develop- . Obtain reproducible . Select from a pre- . Analyze GPCR mutants, ment and method resultsusing optimized defined panel or create orthologs or novel cell transfer to global sites culture anddetection a personalized panel backgrounds reagents with specific assays Can’t Find Your Assay on Our Menu? Try Our Custom Assay Development Services For information on requesting a custom assay development, please visit discoverx.com/cad. w discoverx.com usa 1.866.448.4864 eu +44.121.260.6142 e [email protected] GPCRome The Largest GPCR Family Coverage MRGPRX3 P2RY11 FFAR3 FFAR2 MRGPRX1 HCAR3 FFAR1 F2RL2 F MRGPRX4 HCAR2 GPCRs HCAR1 OXER1 MRGPRX2 2 GPR31 UTS2R MRGPRD R MRGP MRGPRE L 2 4 MRGPRF 3 P2RY8 F2R F2RL1 GPR55 GPR18 GPR20 GPR92 GPR35 OXGR1 MAS1L GPR91 P2RY1 TBXA2R P2RY6 PTGER1 RG P2RY FR MAS1 P2RY GPR132 GPR65 PTGER3PTGFR GPR4 PTGER2 GPR68 PTA GPR34 PTGDR GPR171 PTGER4 GPR87 PTGIR P2RY14 P2RY12 P2RY13 LGR6 GPR183 CYSLTR1 LGR5 CYSLTR2 LGR4 GPR17 LHCGRTSHR GPR174 P2RY10 FSHR GPR23 RXFP2 LPAR6 RXFP1 GPR152 LTB4R OPN5 LTB4R2 GPR85OPN3 C5AR1 GPR173 C5AR2 GPR27 GPR1 GPBAR1 C3AR1 CMKLR1 GPR88 GPR135 GPR33 PTGDR2 GPR62 GPR32 GPR61 FPR1 GPR78 FPR2 GPR26 FPR3 GPR75 KISS1R GPR150 GALR1 GALR2 GALR3 ADRA2C MCHR1 ADRA2A MCHR2 ADRA2B OPRL1 ADRA1B OPRK1 OPRD1 ADRA1A OPRM1 ADRA1D NPBWR1 HTR4 NPBWR2TR1 HRH2 SS DRD3 SSTR4TR2 DRD2 SS SSTR3 DRD4 SSTR5 ADRB2 ER1 ADRB1 GP RXFP3 ADRB3 RXFP4 HTR6 AGTRL1 HTR1F GPR25 HTR1E GPR15 HTR1D AGTR1 HTR1B AGTR2 HTR1A Class A BDKRB1 DRD5 BDKRB2 DRD1 CXCR7 HTR7 GPR182 HTR5A CCBP2 TAAR8 XCR1 TAAR6 CCRL2 AR9 CX3CR1 TA CCR8 TAAR5 CCR4 TAAR3 CCR1 TAAR2 CCR3 TAAR1 CCR2 HRH1 CCR5 HTR2C CXCR1 HTR2A CXCR2 HTR2B CXCR5 CHRM5 CCR10 CHRM1 CXCR3 CHRM3 CXCR4 CX CHRM4 CCRL1CR6 CHRM2 HRH4 CCR9 HRH3 CCR6 CCR7 EDG3 GPR161 EDG1 GPR101 EDG5 GPR84 EDG8 Class B Class C GPR50 EDG6 MTNR1A
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • Gene Expression Polarization
    Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression This information is current as of September 27, 2021. Fernando O. Martinez, Siamon Gordon, Massimo Locati and Alberto Mantovani J Immunol 2006; 177:7303-7311; ; doi: 10.4049/jimmunol.177.10.7303 http://www.jimmunol.org/content/177/10/7303 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2006/11/03/177.10.7303.DC1 Material http://www.jimmunol.org/ References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/10/7303.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 Fernando O.
    [Show full text]
  • The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/02/mol.116.107904.DC1 1521-0111/91/5/518–532$25.00 https://doi.org/10.1124/mol.116.107904 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:518–532, May 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes s Katharina Simon, Nicole Merten, Ralf Schröder, Stephanie Hennen, Philip Preis, Nina-Katharina Schmitt, Lucas Peters, Ramona Schrage,1 Celine Vermeiren, Michel Gillard, Klaus Mohr, Jesus Gomeza, and Evi Kostenis Molecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology (K.S., N.M., Ral.S., S.H., P.P., N.-K.S, L.P., J.G., E.K.), Research Training Group 1873 (K.S., E.K.), Pharmacology and Toxicology Section, Institute of Pharmacy (Ram.S., K.M.), University of Bonn, Bonn, Germany; UCB Pharma, CNS Research, Braine l’Alleud, Belgium (C.V., M.G.). Downloaded from Received December 16, 2016; accepted March 1, 2017 ABSTRACT Pairing orphan G protein–coupled receptors (GPCRs) with their using eight distinct functional assay platforms based on label- cognate endogenous ligands is expected to have a major im- free pathway-unbiased biosensor technologies, as well as molpharm.aspetjournals.org pact on our understanding of GPCR biology. It follows that the canonical second-messenger or biochemical assays. Appraisal reproducibility of orphan receptor ligand pairs should be of of GPR17 activity can be accomplished with neither the coapplica- fundamental importance to guide meaningful investigations into tion of both ligand classes nor the exogenous transfection of partner the pharmacology and function of individual receptors.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Genomic Selection Signatures in Sheep from the Western Pyrenees Otsanda Ruiz-Larrañaga, Jorge Langa, Fernando Rendo, Carmen Manzano, Mikel Iriondo, Andone Estonba
    Genomic selection signatures in sheep from the Western Pyrenees Otsanda Ruiz-Larrañaga, Jorge Langa, Fernando Rendo, Carmen Manzano, Mikel Iriondo, Andone Estonba To cite this version: Otsanda Ruiz-Larrañaga, Jorge Langa, Fernando Rendo, Carmen Manzano, Mikel Iriondo, et al.. Genomic selection signatures in sheep from the Western Pyrenees. Genetics Selection Evolution, BioMed Central, 2018, 50 (1), pp.9. 10.1186/s12711-018-0378-x. hal-02405217 HAL Id: hal-02405217 https://hal.archives-ouvertes.fr/hal-02405217 Submitted on 11 Dec 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Ruiz-Larrañaga et al. Genet Sel Evol (2018) 50:9 https://doi.org/10.1186/s12711-018-0378-x Genetics Selection Evolution RESEARCH ARTICLE Open Access Genomic selection signatures in sheep from the Western Pyrenees Otsanda Ruiz‑Larrañaga1* , Jorge Langa1, Fernando Rendo2, Carmen Manzano1, Mikel Iriondo1 and Andone Estonba1 Abstract Background: The current large spectrum of sheep phenotypic diversity
    [Show full text]
  • The Biglen-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning
    Neuropsychopharmacology (2017) 42, 2527–2536 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning ,1 1 2 3 3 1 Erin N Bobeck* , Ivone Gomes , Darlene Pena , Kirstie A Cummings , Roger L Clem , Mihaly Mezei and ,1 Lakshmi A Devi* 1 2 Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Departamento de Bioquímica, Instituto 3 de Química, Universidade de São Paulo, São Paulo, Brazil; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA – Studies show that neuropeptide receptor systems in the basolateral amygdala (BLA) play an important role in the pathology of anxiety and other mood disorders. Since GPR171, a recently deorphanized receptor for the abundant neuropeptide BigLEN, is expressed in the BLA, we investigated its role in fear and anxiety-like behaviors. To carry out these studies we identified small molecule ligands using a homology model of GPR171 to virtually screen a library of compounds. One of the hits, MS0021570_1, was identified as a GPR171 antagonist based on its ability to block (i) BigLEN-mediated activation of GPR171 in heterologous cells, (ii) BigLEN-mediated hyperpolarization of BLA pyramidal neurons, and (iii) feeding induced by DREADD-mediated activation of BigLEN containing AgRP neurons in the arcuate nucleus. The role of GPR171 in anxiety-like behavior or fear conditioning was evaluated following systemic or intra-BLA administration of MS0021570_1, as well as following lentiviral-mediated knockdown of GPR171 in the BLA.
    [Show full text]
  • G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte
    www.nature.com/scientificreports OPEN G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte Diferentiation in Response Received: 11 May 2017 Accepted: 2 October 2017 to Lysolecithin-Induced Published: xx xx xxxx Demyelination Changqing Lu1,2, Lihua Dong2, Hui Zhou3, Qianmei Li3, Guojiao Huang3, Shu jun Bai3 & Linchuan Liao1 Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS). A variety of brain disorders from “classical” demyelinating diseases, such as multiple sclerosis, stroke, schizophrenia, depression, Down syndrome and autism, are shown myelination defects. Oligodendrocyte myelination is regulated by a complex interplay of intrinsic, epigenetic and extrinsic factors. Gpr17 (G protein- coupled receptor 17) is a G protein-coupled receptor, and has been identifed to be a regulator for oligodendrocyte development. Here, we demonstrate that the absence of Gpr17 enhances remyelination in vivo with a toxin-induced model whereby focal demyelinated lesions are generated in spinal cord white matter of adult mice by localized injection of LPC(L-a-lysophosphatidylcholine). The increased expression of the activated form of Erk1/2 (phospho-Erk1/2) in lesion areas suggested the potential role of Erk1/2 activity on the Gpr17-dependent modulation of myelination. The absence of Gpr17 enhances remyelination is correlate with the activated Erk1/2 (phospho-Erk1/2).Being a membrane receptor, Gpr17 represents an ideal druggable target to be exploited for innovative regenerative approaches to acute and chronic CNS diseases. Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS), and as such, wrap layers of lipid-dense insulating myelin around axons1. Mature oligodendrocytes have also been shown to provide met- abolic support to axons through transport systems within myelin, which may help prevent neurodegeneration2.
    [Show full text]
  • Supplementary Material
    Supplementary Material Table S1: Significant downregulated KEGGs pathways identified by DAVID following exposure to five cinnamon- based phenylpropanoids (p < 0.05). p-value Term: Genes (Benjamini) Cytokine-cytokine receptor interaction: FASLG, TNFSF14, CXCL11, IL11, FLT3LG, CCL3L1, CCL3L3, CXCR6, XCR1, 2.43 × 105 RTEL1, CSF2RA, TNFRSF17, TNFRSF14, CCNL2, VEGFB, AMH, TNFRSF10B, INHBE, IFNB1, CCR3, VEGFA, CCR2, IL12A, CCL1, CCL3, CXCL5, TNFRSF25, CCR1, CSF1, CX3CL1, CCL7, CCL24, TNFRSF1B, IL12RB1, CCL21, FIGF, EPO, IL4, IL18R1, FLT1, TGFBR1, EDA2R, HGF, TNFSF8, KDR, LEP, GH2, CCL13, EPOR, XCL1, IFNA16, XCL2 Neuroactive ligand-receptor interaction: OPRM1, THRA, GRIK1, DRD2, GRIK2, TACR2, TACR1, GABRB1, LPAR4, 9.68 × 105 GRIK5, FPR1, PRSS1, GNRHR, FPR2, EDNRA, AGTR2, LTB4R, PRSS2, CNR1, S1PR4, CALCRL, TAAR5, GABRE, PTGER1, GABRG3, C5AR1, PTGER3, PTGER4, GABRA6, GABRA5, GRM1, PLG, LEP, CRHR1, GH2, GRM3, SSTR2, Chlorogenic acid Chlorogenic CHRM3, GRIA1, MC2R, P2RX2, TBXA2R, GHSR, HTR2C, TSHR, LHB, GLP1R, OPRD1 Hematopoietic cell lineage: IL4, CR1, CD8B, CSF1, FCER2, GYPA, ITGA2, IL11, GP9, FLT3LG, CD38, CD19, DNTT, 9.29 × 104 GP1BB, CD22, EPOR, CSF2RA, CD14, THPO, EPO, HLA-DRA, ITGA2B Cytokine-cytokine receptor interaction: IL6ST, IL21R, IL19, TNFSF15, CXCR3, IL15, CXCL11, TGFB1, IL11, FLT3LG, CXCL10, CCR10, XCR1, RTEL1, CSF2RA, IL21, CCNL2, VEGFB, CCR8, AMH, TNFRSF10C, IFNB1, PDGFRA, EDA, CXCL5, TNFRSF25, CSF1, IFNW1, CNTFR, CX3CL1, CCL5, TNFRSF4, CCL4, CCL27, CCL24, CCL25, CCL23, IFNA6, IFNA5, FIGF, EPO, AMHR2, IL2RA, FLT4, TGFBR2, EDA2R,
    [Show full text]
  • G Protein-Coupled Receptors in Stem Cell Maintenance and Somatic Reprogramming to Pluripotent Or Cancer Stem Cells
    BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-14-250 Title: G protein-coupled receptors in stem cell maintenance and somatic reprogramming to pluripotent or cancer stem cells Article Type: Mini Review Keywords: G protein-coupled receptors; stem cell maintenance; somatic reprogramming; cancer stem cells; pluripotent stem cell Corresponding Author: Ssang-Goo Cho Authors: Ssang-Goo Cho1,*, Hye Yeon Choi1, Subbroto Kumar Saha1, Kyeongseok Kim1, Sangsu Kim1, Gwang-Mo Yang1, BongWoo Kim1, Jin-hoi Kim1 Institution: 1Department of Animal Biotechnology, Animal Resources Research Center, and Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, Republic of Korea, UNCORRECTED PROOF 1 G protein-coupled receptors in stem cell maintenance and somatic reprogramming to 2 pluripotent or cancer stem cells 3 4 Hye Yeon Choi, Subbroto Kumar Saha, Kyeongseok Kim, Sangsu Kim, Gwang-Mo 5 Yang, BongWoo Kim, Jin-hoi Kim, and Ssang-Goo Cho 6 7 Department of Animal Biotechnology, Animal Resources Research Center, and 8 Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 9 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, Republic of Korea 10 * 11 Address correspondence to Ssang-Goo Cho, Department of Animal Biotechnology and 12 Animal Resources Research Center. Konkuk University, 120 Neungdong-ro, Gwangjin- 13 gu, Seoul 143-701, Republic of Korea. Tel: 82-2-450-4207, Fax: 82-2-450-1044, E-mail: 14 [email protected] 15 16 17 18 19 1 UNCORRECTED PROOF 20 Abstract 21 The G protein-coupled receptors (GPCRs) compose the third largest gene family in the 22 human genome, representing more than 800 distinct genes and 3–5% of the human genome.
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, DC 20549
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington 001-34475 91-1663741 (State or other jurisdiction of (Commission (IRS Employer incorporation) File Number) Identification No.) 1420 Fifth Avenue, Suite 2600 Seattle, Washington 98101 (Address of principal executive offices, including zip code) (206) 676-5000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 2.02 Results of Operation and Financial Condition. On May 10, 2012, Omeros Corporation issued a press release announcing financial results for the three months ended March 31, 2012. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
    [Show full text]